AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|November 21, 2007
Humira to gain fifth indication?
Abbott Laboratories has received a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis.
Advertisement
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted Abbott Laboratories a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis. If fully approved, psoriasis will be the fifth disease indication for Humira, after rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.
Abbott is also hoping for FDA approval for this indication.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
Understanding the Latest with MFN Pricing and What It Means to Pharma
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5